Hameed ullah



Technectium-99m Pentavalent Dimecaptosuccinic acid (99mTc(V)-DMSA) scintigraphy was performed in a patient with histopathologically proven medullary thyroid carcinoma having high level of calcitonin using a locally formulated kit. Marked uptake of the radiotracer was observed by the locally metastatic foci. The same patient was then subjected to somatostatin receptor scintigraphy (OctreoScan) and the results were found comparable. Both the scanning was completed within 24hrs with good quality images. In house preparation from renal DMSA kit, better resolution, good stability and easy procedure with minimum cost make 99mTc(V)-DMSA, a good  imaging agent for visualization of medullary thyroid carcinoma in centre’s where 99mTc-EDDA/HYNIC-Tyr3-Octreotide is not available.        

Full Text:




Leboulleux S, Baudin E, Travagli J, Schlumberger M. Medullary thyroid carcinoma.Clin Endocrinol (Oxf) 2004;61:299–310.

Skoura E. Depicting Medullary Thyroid Cancer Recurrence: The Past and the Future of Nuclear Medicine Imaging. Int J Endocrinol Metab. 2013 Oct; 11(4): e8156.

Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007; 92:450–5.

Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19(6): 565–612. doi: 10.1089/thy.2008.0403.

Laverman P, Sosabowski JK, Boerman OC, Oyen WJ. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1:S78-92.

Sippel RS, Kunnimalaiyaan M and Chen H. Current Management of Medullary Thyroid Cancer. Oncologist. 2008 May; 13(5): 539-47.

Ha EJ, Baek JH, Na DG, Kim Jh, Kim JK, Min HS, Song DE, Lee KE and Shong YK.The Role of Core Needle Biopsy and Its Impact on Surgical Management in Patients with Medullary Thyroid Cancer: Clinical Experience at 3 Medical Institutions. Am. J. Neuroradiol. 2015; 36:1512-1517.

Kapur S, Xiao H, Zakowski MF, Hameed MR, Levin MB. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature. World J Oncol. 2014; 5(2): 81-89.

Khan AU, Hameedullah, Bahadur A, Khattak MR and Shah AS. Mediastinal spread of medullary thyroid carcinoma imaged by locally formulated 99mTc-DMSA(V). Pak J of Nucl Med 2013; 1(3): 73-77.

Niafer M, Dabiri S, Bozorgi F, Niafer F and Gholami N. Metastatic medullary thyroid carcinoma: a case report. J Res Med Sci. 2011; 16(4): 568-573.

Czepczyński R, Parisella MG, Kosowicz J, Mikołajczak R, Ziemnicka K, Gryczyńska M, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34: 1635–45.

Nicolini S, Ambrosini V, Fantini L, Fanti S. 68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level. Clin Nucl Med. 2012; 37: 591–2.

Evangelia S, Maria P, Ioannis DE. The Role of Nuclear Medicine in Imaging and Therapy of Neuroendocrine Tumors. Hospital Chronicles.2012; 7(2): 81–90.

Krishnamurthy A, Kumar RK, Ravishankaran P, Ramshankar V, Begum ASB and Rangarajan GK. Exploring the role of technitium-99m dimercaptosuccinyl acid (V) scan in medullary carcinoma thyroid patients with postoperative persistent hypercalcitoninemia in the era of positron emission tomography-computerized tomography. Indian J Nucl Med. 2014 Jul-Sep; 29(3): 146–150.

Shah S, Purandare N, Agrawal A, and Rangarajan V. A pictoral review on somatostatin receptor scintigraphy in neuroendocrine tumors: The role of multimodality imaging with SRS and GLUT receptor imaging with FDG PET-CT. Indian J Radiol Imaging. 2012 Oct-Dec; 22(4): 267–275.

Abdullah MM, Almohanadi S, Abulhuda F, Usmani S. Pentavalent [99mTc] DMSA and Serum Calcitonin in Evaluation of patients with Medullary Carcinoma of the Thyroid. AAMJ, Vol.6, N. 3, September, 2008.

Clarke S, Εll PJ, Gambhir SS. In: Medullary thyroid cancer. 3 ed. Clarke S, Εll PJ, Gambhir SS, editors. Churcill Livingstone; 2004. pp. 165–174.

Dabiri S. [99mTc-DMSA (V)] in Detection of Metastases of Medullary Thyroid Carcinoma. Iran J Nucl Med 2006; 14(26): 15-24.

Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2004; 48(2):150–63.

Bozkurt MF, Ugur O, Banti E,Grassetto G, Rubello D. Functional nuclear medicine imaging of medullary thyroid carcinoma. Nucl Med Commun 2008; 29(11): 934-42.

Khan AU, Thein TM, Khan AA, Khan SM. Role of locally formulated I131MIBG in imaging of neuroendocrine tumors. J Coll Physcian Surg Pak. 2001; 11(10): 617-21.

Sager S, Kabasakal L, Ocak M, Maecke H, Uslu L, Halaç M, Asa S, Sager G, Önsel C and Kanmaz B. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images. Nucl Med Commun. 2013 Dec; 34(12): 1190–1195.

Kulkarni HR, Singh A, Baum RP. Advances in the Diagnosis of Neuroendocrine Neoplasms. Seminars in Nuclear Medicine. Sep 2016, Vol. 46(5): 395-404.

Prasad V, Fetscher S and Baum RP. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine’s view. J Pharm Pharmaceut Sci. 2007: 321s-337s.

Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001; 26(8): 683-8.

Shukla J and Mittal BR. Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy. Indian J Nucl Med. 2015 Oct-Dec; 30(4): 295–302. doi: 10.4103/0972-3919.164015.

Adalet I, Demirkale P, Unal S, Ouz H, Alagöl F, Cantez S. Disappointing results with Tc-99m tetrofosmin for detecting medullary thyroid carcinoma metastases comparison with Tc-99m (V)DMSA and TI-201. Clin Nucl Med. 1999; 24: 678–83.


  • There are currently no refbacks.

© Copyright PJR 2008-